Assembly Biosciences Inc

$ 13.65 <%= Resources.Global.txtUp %>
Updated 15/07/2019
Change % 0.44% Stock price increasing
Change 0.06 Stock price increasing
Volume 113,647
High $ 13.84
Low $ 13.32
Open $ 13.61
Prev close $ 13.59
# of shares 25.55M
Market cap 348.75M USD

Market closed
Assembly Biosciences Inc
Market is closed, opens at 14:30
Price development Latest 1 week 1 month 3 months 6 months 1 year
  13.65 0.5% Stock price increasing -9.0% Stock price decreasing -15.2% Stock price decreasing -35.8% Stock price decreasing -68.7% Stock price decreasing
Powered by TradingView

News about Assembly Biosciences Inc

  • English
  • Regulatory news

Company profile

Assembly Biosciences Inc is a clinical stage biotechnology company. It is advancing two innovative platform programs, a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
17 July 2019 06:15:03
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB6 - 2019-07-17 07:15:03 - 2019-07-17 06:15:03 - 1000 - Website: OKAY